UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: July 9, 2024
Commission File Number: 001-38844
GENFIT S.A.
(Translation of registrant’s name into English)
Parc Eurasanté
885, avenue Eugène Avinée
59120 Loos, France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
|
|
| |
|
|
|
GENFIT S.A. |
| |
|
|
|
| Date: July 9, 2024 |
|
|
|
By: |
|
/s/ Pascal PRIGENT |
| |
|
|
|
|
|
Name: Pascal PRIGENT |
| |
|
|
|
|
|
Title: Chief Executive Officer |
Exhibit 99.1
GENFIT:
Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States),
Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical
company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year
report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit
Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2024:
During the first half of 2024, total trading was:
| · | On the buy side: 1 515,865 shares for a total amount of €5,499,002.56 |
| · | On the sell side: 1 532,677 shares for a total amount of €5,669,272.79 During this same period, the number of trades were: |
As a reminder, upon signing of the contract, the following
resources appeared on the liquidity account:
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical
company committed to improving the lives of patients with rare, life-threatening liver diseases whose
medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific
heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs
at various stages of development. The Company focuses on Acute-on- Chronic Liver Failure (ACLF). Its ACLF franchise includes five
assets under development: VS-01, NTZ,
 | 1 |
SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms
of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea
cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced
stages, and in pre-commercialization, was exemplified in the FDA’s accelerated approval of IQIRVO® (elafibranor1) for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+®
in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non- alcoholic steatohepatitis) and TS-01 focusing
on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich
(Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market
in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake
in the Company's capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including,
but not limited to statements about GENFIT’s research and development programs. The use of certain words, such as "believe",
"potential", "expect", “target”, “may”, “will”, "should", "could",
"if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations
are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are
subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed
in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties
inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our
ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our
drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued
ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s
public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal
Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"),
which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents
and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report
on Form 20-F filed with the SEC on April 5, 2024 and
1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark IQIRVO®.
| 2 |
subsequent filings and reports filed with the AMF or SEC
or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company
and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive
of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document.
Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information
or statements, whether as a result of new information, future events or otherwise.
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
PRESS RELATIONS | Media
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
| 3 |
| |
Buy side |
Sell-side |
| Date |
Number of executions |
Number of shares |
Traded amounts in EUR |
Number of executions |
Number of shares |
Traded amounts in EUR |
| TOTAL |
2 256 |
1 515
865 |
5 499 002,56 |
2 012 |
1 532 677 |
5 669 272,79 |
| 02/01/2024 |
20 |
15001 |
54 728,60 |
44 |
67299 |
246 531,04 |
| 03/01/2024 |
20 |
24570 |
92 373,37 |
33 |
27528 |
104 315,70 |
| 04/01/2024 |
27 |
21790 |
81 057,27 |
38 |
12724 |
47 598,19 |
| 05/01/2024 |
46 |
40442 |
146 853,80 |
20 |
8106 |
29 367,79 |
| 08/01/2024 |
27 |
26976 |
94 566,26 |
26 |
17813 |
63 060,34 |
| 09/01/2024 |
37 |
24367 |
86 272,58 |
18 |
25934 |
92 719,50 |
| 10/01/2024 |
26 |
29612 |
102 891,63 |
7 |
8128 |
28 366,80 |
| 11/01/2024 |
26 |
18543 |
63 060,66 |
11 |
9887 |
33 985,77 |
| 12/01/2024 |
11 |
12166 |
41 322,79 |
8 |
14152 |
48 363,75 |
| 15/01/2024 |
22 |
23972 |
80 216,54 |
10 |
5131 |
17 240,16 |
| 16/01/2024 |
40 |
28677 |
94 811,61 |
14 |
14428 |
48 312,01 |
| 17/01/2024 |
116 |
39086 |
124 922,76 |
11 |
13537 |
43 114,40 |
| 18/01/2024 |
17 |
17938 |
57 074,23 |
13 |
15101 |
48 777,14 |
| 19/01/2024 |
17 |
8516 |
26 962,76 |
6 |
4965 |
15 909,25 |
| 22/01/2024 |
23 |
21001 |
69 693,29 |
95 |
96736 |
323 324,60 |
| 23/01/2024 |
35 |
19854 |
71 395,38 |
59 |
43854 |
157 143,79 |
| 24/01/2024 |
18 |
20883 |
76 614,30 |
36 |
30883 |
114 842,76 |
| 25/01/2024 |
29 |
27704 |
101 327,66 |
25 |
27704 |
102 086,47 |
| 26/01/2024 |
27 |
39500 |
142 628,58 |
2 |
2 |
7,34 |
| 29/01/2024 |
32 |
17001 |
61 163,65 |
23 |
30200 |
109 590,97 |
| 30/01/2024 |
22 |
10488 |
39 125,59 |
13 |
11300 |
42 502,01 |
| 31/01/2024 |
4 |
2091 |
7 707,91 |
1 |
1 |
3,72 |
| 01/02/2024 |
25 |
25594 |
92 362,86 |
7 |
5429 |
19 816,01 |
| 02/02/2024 |
18 |
12001 |
43 093,55 |
28 |
17171 |
61 917,94 |
| 05/02/2024 |
22 |
27832 |
98 386,12 |
29 |
18473 |
65 209,69 |
| 06/02/2024 |
8 |
6000 |
21 255,00 |
40 |
72699 |
259 700,76 |
| 07/02/2024 |
26 |
30739 |
108 303,64 |
5 |
5001 |
18 103,62 |
| 08/02/2024 |
24 |
14467 |
50 178,93 |
13 |
18701 |
65 251,34 |
| 09/02/2024 |
15 |
14885 |
51 343,43 |
7 |
7945 |
27 618,09 |
| 4 |
| 12/02/2024 |
52 |
42657 |
154 536,50 |
42 |
66333 |
238 579,90 |
| 13/02/2024 |
30 |
19660 |
68 994,80 |
14 |
4660 |
16 820,50 |
| 14/02/2024 |
6 |
5001 |
17 340,97 |
3 |
5001 |
17 503,50 |
| 15/02/2024 |
16 |
15002 |
52 269,52 |
18 |
12531 |
43 910,25 |
| 16/02/2024 |
3 |
5001 |
17 828,57 |
19 |
11971 |
42 940,22 |
| 19/02/2024 |
15 |
10499 |
37 096,54 |
6 |
4450 |
15 903,01 |
| 20/02/2024 |
21 |
15170 |
52 462,26 |
3 |
2501 |
8 778,48 |
| 21/02/2024 |
26 |
20035 |
67 418,38 |
7 |
3092 |
10 450,99 |
| 22/02/2024 |
16 |
12451 |
41 475,28 |
20 |
24141 |
81 334,65 |
| 23/02/2024 |
7 |
10031 |
33 604,35 |
4 |
3154 |
10 723,57 |
| 26/02/2024 |
11 |
7182 |
23 630,29 |
11 |
7182 |
23 773,93 |
| 27/02/2024 |
2 |
2494 |
8 280,08 |
4 |
6752 |
22 672,27 |
| 28/02/2024 |
16 |
20037 |
66 137,33 |
13 |
9292 |
30 539,09 |
| 29/02/2024 |
32 |
29383 |
94 700,53 |
4 |
4534 |
14 651,98 |
| 01/03/2024 |
11 |
9765 |
30 847,34 |
16 |
15863 |
50 722,42 |
| 04/03/2024 |
16 |
14225 |
46 783,46 |
20 |
12041 |
39 944,45 |
| 05/03/2024 |
24 |
18730 |
60 015,98 |
3 |
2501 |
8 103,24 |
| 06/03/2024 |
17 |
7334 |
23 581,89 |
5 |
6907 |
22 315,34 |
| 07/03/2024 |
29 |
14223 |
45 711,30 |
11 |
9223 |
29 820,73 |
| 08/03/2024 |
7 |
9489 |
30 243,25 |
6 |
5105 |
16 318,80 |
| 11/03/2024 |
20 |
10595 |
33 999,25 |
16 |
11247 |
36 350,64 |
| 12/03/2024 |
7 |
2316 |
7 455,46 |
6 |
6475 |
20 981,01 |
| 13/03/2024 |
11 |
10101 |
32 563,70 |
28 |
18414 |
60 030,74 |
| 14/03/2024 |
7 |
8614 |
27 799,53 |
7 |
4902 |
15 881,55 |
| 15/03/2024 |
25 |
18874 |
59 776,03 |
13 |
7416 |
23 517,55 |
| 18/03/2024 |
21 |
10233 |
32 463,58 |
8 |
12501 |
39 915,69 |
| 19/03/2024 |
20 |
13621 |
44 243,19 |
29 |
18210 |
59 488,06 |
| 20/03/2024 |
19 |
12925 |
41 349,14 |
18 |
12501 |
40 390,73 |
| 21/03/2024 |
12 |
4921 |
15 840,99 |
6 |
3921 |
12 693,26 |
| 22/03/2024 |
8 |
3001 |
9 953,27 |
17 |
9425 |
31 091,10 |
| 25/03/2024 |
2 |
2501 |
8 303,35 |
5 |
5001 |
16 728,35 |
| 26/03/2024 |
10 |
8001 |
26 583,40 |
4 |
2415 |
8 138,55 |
| 27/03/2024 |
6 |
4587 |
15 220,49 |
8 |
5001 |
16 753,30 |
| 28/03/2024 |
8 |
7915 |
26 048,66 |
9 |
7501 |
24 990,86 |
| 02/04/2024 |
19 |
15001 |
49 115,82 |
5 |
2267 |
7 571,78 |
| 03/04/2024 |
6 |
5001 |
16 065,71 |
5 |
7501 |
24 340,75 |
| 04/04/2024 |
14 |
8181 |
26 591,69 |
2 |
2501 |
8 178,27 |
| 05/04/2024 |
57 |
27274 |
86 585,13 |
3 |
3001 |
9 593,24 |
| 08/04/2024 |
14 |
6720 |
21 244,81 |
28 |
12493 |
40 004,46 |
| 09/04/2024 |
10 |
4323 |
13 873,59 |
14 |
11823 |
38 395,07 |
| 5 |
| 10/04/2024 |
6 |
4549 |
14 692,36 |
8 |
3049 |
9 893,79 |
| 11/04/2024 |
8 |
4501 |
14 818,24 |
16 |
14005 |
46 626,71 |
| 12/04/2024 |
10 |
2501 |
8 388,35 |
8 |
3247 |
11 027,40 |
| 15/04/2024 |
22 |
8660 |
28 376,48 |
2 |
2001 |
6 643,32 |
| 16/04/2024 |
30 |
10400 |
33 239,44 |
10 |
7651 |
24 585,80 |
| 17/04/2024 |
11 |
6459 |
20 550,02 |
8 |
4501 |
14 350,67 |
| 18/04/2024 |
2 |
1501 |
4 758,19 |
5 |
3001 |
9 573,19 |
| 19/04/2024 |
25 |
4284 |
13 519,15 |
4 |
548 |
1 726,21 |
| 22/04/2024 |
6 |
942 |
2 985,58 |
10 |
8646 |
27 778,91 |
| 23/04/2024 |
11 |
2500 |
8 080,00 |
12 |
4148 |
13 477,52 |
| 24/04/2024 |
9 |
2501 |
8 030,74 |
1 |
1 |
3,24 |
| 25/04/2024 |
8 |
3808 |
12 149,46 |
1 |
1 |
3,21 |
| 26/04/2024 |
2 |
401 |
1 267,18 |
11 |
1127 |
3 597,64 |
| 29/04/2024 |
1 |
1 |
3,21 |
9 |
1875 |
6 038,76 |
| 30/04/2024 |
11 |
2295 |
7 366,54 |
4 |
1501 |
4 878,23 |
| 02/05/2024 |
2 |
153 |
489,6 |
2 |
272 |
883,95 |
| 03/05/2024 |
11 |
1001 |
3 238,21 |
8 |
3480 |
11 367,45 |
| 06/05/2024 |
4 |
2030 |
6 657,20 |
6 |
4251 |
14 050,75 |
| 07/05/2024 |
1 |
1 |
3,26 |
3 |
2002 |
6 546,54 |
| 08/05/2024 |
4 |
1501 |
5 010,82 |
27 |
23822 |
79 591,21 |
| 09/05/2024 |
3 |
941 |
3 158,57 |
11 |
4247 |
14 325,09 |
| 10/05/2024 |
8 |
2026 |
6 856,51 |
29 |
15855 |
54 238,53 |
| 13/05/2024 |
12 |
5776 |
19 620,84 |
29 |
3259 |
11 351,81 |
| 14/05/2024 |
5 |
1180 |
3 984,13 |
6 |
1918 |
6 544,20 |
| 15/05/2024 |
11 |
2476 |
8 314,14 |
29 |
13980 |
47 819,99 |
| 16/05/2024 |
1 |
1 |
3,47 |
5 |
1001 |
3 465,80 |
| 17/05/2024 |
10 |
2401 |
8 291,30 |
7 |
6101 |
21 244,84 |
| 20/05/2024 |
1 |
1 |
3,48 |
64 |
26344 |
92 536,99 |
| 21/05/2024 |
7 |
3589 |
13 223,49 |
6 |
1338 |
4 940,65 |
| 22/05/2024 |
6 |
3293 |
12 137,64 |
44 |
18546 |
72 575,69 |
| 23/05/2024 |
24 |
8917 |
36 812,14 |
29 |
16372 |
68 980,48 |
| 24/05/2024 |
7 |
2370 |
9 717,24 |
19 |
4370 |
18 355,57 |
| 27/05/2024 |
18 |
5251 |
21 839,22 |
7 |
3751 |
15 724,19 |
| 28/05/2024 |
2 |
501 |
2 144,20 |
9 |
4202 |
17 978,55 |
| 29/05/2024 |
1 |
1 |
4,31 |
24 |
18300 |
83 270,49 |
| 30/05/2024 |
5 |
1501 |
8 054,83 |
24 |
10501 |
54 139,80 |
| 31/05/2024 |
34 |
29001 |
142 793,38 |
14 |
6001 |
31 625,81 |
| 03/06/2024 |
22 |
21001 |
98 104,70 |
34 |
35001 |
168 654,77 |
| 04/06/2024 |
6 |
6001 |
29 640,08 |
24 |
9001 |
45 605,10 |
| 05/06/2024 |
33 |
28453 |
137 739,27 |
83 |
35453 |
173 952,98 |
| 6 |
| 06/06/2024 |
4 |
2001 |
9 604,80 |
30 |
24526 |
120 530,08 |
| 07/06/2024 |
7 |
5001 |
24 544,81 |
36 |
22476 |
112 524,30 |
| 10/06/2024 |
12 |
6001 |
29 204,95 |
15 |
8001 |
39 714,88 |
| 11/06/2024 |
26 |
16001 |
79 795,55 |
28 |
16001 |
80 764,73 |
| 12/06/2024 |
45 |
26201 |
120 430,80 |
24 |
16627 |
76 926,15 |
| 13/06/2024 |
65 |
40001 |
179 794,49 |
6 |
7575 |
35 330,25 |
| 14/06/2024 |
70 |
45001 |
188 049,28 |
14 |
21001 |
86 794,40 |
| 17/06/2024 |
25 |
15001 |
56 793,79 |
11 |
15001 |
57 808,75 |
| 18/06/2024 |
11 |
6501 |
25 780,30 |
14 |
8001 |
32 584,07 |
| 19/06/2024 |
26 |
17001 |
66 196,96 |
4 |
6001 |
23 833,93 |
| 20/06/2024 |
13 |
4001 |
14 903,73 |
12 |
7501 |
28 406,21 |
| 21/06/2024 |
38 |
12001 |
45 438,91 |
9 |
6001 |
22 783,88 |
| 24/06/2024 |
28 |
17001 |
62 773,81 |
13 |
8001 |
29 388,79 |
| 25/06/2024 |
17 |
9001 |
33 182,01 |
14 |
11001 |
41 373,66 |
| 26/06/2024 |
16 |
5001 |
18 363,72 |
15 |
11001 |
40 491,05 |
| 27/06/2024 |
3 |
1001 |
3 688,72 |
7 |
4001 |
14 888,72 |
| 28/06/2024 |
17 |
9709 |
34 658,80 |
6 |
2709 |
9 529,88 |
|
7 |
Genfit (PK) (USOTC:GNFTF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Genfit (PK) (USOTC:GNFTF)
Historical Stock Chart
From Jan 2024 to Jan 2025
